Assert-IQ vs VX1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

VX1

by Volta Medical

AI Verdict

Assert-IQ focuses on long-term, continuous cardiac monitoring and arrhythmia detection for diagnosis and management of suspected heart rhythm disorders. In contrast, VX1 is an AI software designed to provide real-time guidance to electrophysiologists specifically during atrial fibrillation and atrial tachycardia ablation procedures. While both leverage AI in cardiology, they address different stages of patient care, with Assert-IQ for diagnostics and VX1 for interventional support.

Choose Assert-IQ if…

Choose Assert-IQ if you require long-term, continuous monitoring for patients with suspected heart rhythm disorders, aiming for comprehensive arrhythmia detection and remote management. This tool is ideal for diagnosing elusive arrhythmias over an extended period and providing proactive alerts for clinicians.

View Assert-IQ →

Choose VX1 if…

Choose VX1 if you are an electrophysiologist seeking real-time, AI-guided assistance during atrial fibrillation and atrial tachycardia ablation procedures. This software is designed to enhance the precision of your ablations by identifying dispersed electrograms, thereby standardizing outcomes and reducing inter-operator variability.

View VX1 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	VX1
Pricing	Unknown	Contact for pricing
Deployment	Subcutaneously implanted device with mobile app connectivity	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Assert-IQ

Assert-IQ offers broader usability for both patients and clinicians through its myMerlin Mobile App for symptom logging and data transmission, along with remote programming capabilities for device adjustments. This provides convenience and streamlines long-term monitoring, whereas VX1's usability is specific to the specialized environment of an EP lab, albeit with a simple interface for specialists.

Clinical Value

Tie

Both tools demonstrate significant clinical value in different areas of cardiac care. Assert-IQ provides long-term, continuous monitoring with advanced AI algorithms for accurate arrhythmia detection and improved diagnosis and management. VX1 offers real-time AI guidance during complex ablation procedures, proven to standardize outcomes and reduce inter-operator variability.

Pricing & Value

Tie

Both Assert-IQ and VX1 employ opaque pricing models, requiring direct contact for institutional pricing, and neither offers a free trial. Without transparent pricing information or detailed cost-benefit analyses, it is not possible to definitively compare their value propositions.

Enterprise Readiness

Assert-IQ

Assert-IQ benefits from being a product of Abbott Medical, a large and established global company, explicitly stating HIPAA compliance and FDA clearance. While Volta Medical is committed to compliance and has FDA clearance, the explicit declaration of HIPAA compliance and a Business Associate Agreement (BAA) was not initially provided in the structured facts for VX1, which is a critical aspect for enterprise adoption.

Innovation

VX1

VX1 demonstrates a higher degree of innovation by applying AI in real-time during complex interventional cardiac ablation procedures to identify specific electrograms and standardize outcomes. This real-time, AI-guided decision support during a live surgical procedure represents a more cutting-edge and transformative application of AI in healthcare compared to Assert-IQ's advanced long-term monitoring, which is an evolution of existing technology.

Support & Docs

Assert-IQ

Abbott Medical, as a large and established medical device company, provides comprehensive support and documentation for Assert-IQ, including detailed clinician and patient manuals, remote monitoring help, and dedicated technical support. While Volta Medical offers user manuals and outlines its compliance commitment, the breadth and depth of support from a global leader like Abbott are generally more extensive.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	VX1
Name	Assert-IQ	VX1
Company	Abbott Medical	Volta Medical
Description	The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders.	Volta Medical's VX1 is an FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Surgical AI
Specialties	Cardiology, Internal Medicine	Cardiology
Key Features (Partial)	Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission	AI-guided real-time identification of dispersed electrograms (EGMs), Assists cardiologists during AFib and atrial tachycardia ablation procedures, Analyzes 3D anatomical and electrical maps of human atria

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and VX1.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application difference between Assert-IQ and VX1?

Assert-IQ is designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. In contrast, VX1 is an AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.

Which patient populations or clinical scenarios are best suited for Assert-IQ versus VX1?

Assert-IQ is suitable for patients requiring long-term, continuous cardiac monitoring for comprehensive arrhythmia detection, aiding in diagnosis and ongoing management. VX1 is specifically designed for patients undergoing atrial fibrillation and atrial tachycardia ablation procedures, assisting electrophysiologists in real-time during these interventions.

What kind of data does each tool provide to the physician, and how is that data utilized?

Assert-IQ provides long-term continuous cardiac monitoring data, advanced arrhythmia detection algorithms, and proactive clinician alerts for diagnosis and ongoing management. VX1 analyzes 3D anatomical and electrical maps of human atria to provide AI-guided real-time identification of dispersed electrograms, assisting directly in ablation procedures.

What is the expected duration of use or engagement with each tool?

Assert-IQ provides long-term continuous cardiac monitoring for up to 6 years, focusing on extended diagnostic and management periods. VX1 is utilized in real-time during specific atrial fibrillation and atrial tachycardia ablation procedures.

Are there specific hardware or software compatibility requirements for VX1 that differ from Assert-IQ's system?

VX1 is designed to be integrated with existing electrophysiology (EP) lab mapping and recording systems and is compatible with most EP recording, 3D navigation systems, and mapping catheters. Assert-IQ is described as an insertable cardiac monitor system with a secure cloud-based data platform, implying its own integrated ecosystem rather than relying on external EP lab hardware for its core function.